Skip to main content
Addgene
Open Menu

pCMV-T7-SpCas9-P2A-EGFP (RTW3027) Citations (10)

Originally described in: Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.
Walton RT, Christie KA, Whittaker MN, Kleinstiver BP Science. 2020 Apr 17;368(6488):290-296. doi: 10.1126/science.aba8853. Epub 2020 Mar 26. PubMed Journal

Articles Citing pCMV-T7-SpCas9-P2A-EGFP (RTW3027)

Articles
Precise DNA cleavage using CRISPR-SpRYgests. Christie KA, Guo JA, Silverstein RA, Doll RM, Mabuchi M, Stutzman HE, Lin J, Ma L, Walton RT, Pinello L, Robb GB, Kleinstiver BP. Nat Biotechnol. 2022 Oct 6. pii: 10.1038/s41587-022-01492-y. doi: 10.1038/s41587-022-01492-y. PubMed

Associated Plasmids
Delete_In situ architecture of Opa1-dependent mitochondrial cristae remodeling. Fry MY, Navarro PP, Qin X, Inde Z, Ananda VY, Lugo CM, Hakim P, Luce BE, Ge Y, McDonald JL, Ali I, Ha LL, Kleinstiver BP, Chan DC, Sarosiek KA, Chao LH. bioRxiv. 2023 Feb 15:2023.01.16.524176. doi: 10.1101/2023.01.16.524176. Preprint. PubMed
PMS1 as a target for splice modulation to prevent somatic CAG repeat expansion in Huntington's disease. McLean ZL, Gao D, Correia K, Roy JCL, Shibata S, Farnum IN, Valdepenas-Mellor Z, Rapuru M, Morini E, Ruliera J, Gillis T, Lucente D, Kleinstiver BP, Lee JM, MacDonald ME, Wheeler VC, Pinto RM, Gusella JF. bioRxiv [Preprint]. 2023 Jul 27:2023.07.25.550489. doi: 10.1101/2023.07.25.550489. PubMed
PAM-flexible genome editing with an engineered chimeric Cas9. Zhao L, Koseki SRT, Silverstein RA, Amrani N, Peng C, Kramme C, Savic N, Pacesa M, Rodriguez TC, Stan T, Tysinger E, Hong L, Yudistyra V, Ponnapati MR, Jacobson JM, Church GM, Jakimo N, Truant R, Jinek M, Kleinstiver BP, Sontheimer EJ, Chatterjee P. Nat Commun. 2023 Oct 4;14(1):6175. doi: 10.1038/s41467-023-41829-y. PubMed

Associated Plasmids
In situ architecture of Opa1-dependent mitochondrial cristae remodeling. Fry MY, Navarro PP, Hakim P, Ananda VY, Qin X, Landoni JC, Rath S, Inde Z, Lugo CM, Luce BE, Ge Y, McDonald JL, Ali I, Ha LL, Kleinstiver BP, Chan DC, Sarosiek KA, Chao LH. EMBO J. 2024 Feb;43(3):391-413. doi: 10.1038/s44318-024-00027-2. Epub 2024 Jan 15. PubMed

Associated Plasmids
Splice modulators target PMS1 to reduce somatic expansion of the Huntington's disease-associated CAG repeat. McLean ZL, Gao D, Correia K, Roy JCL, Shibata S, Farnum IN, Valdepenas-Mellor Z, Kovalenko M, Rapuru M, Morini E, Ruliera J, Gillis T, Lucente D, Kleinstiver BP, Lee JM, MacDonald ME, Wheeler VC, Mouro Pinto R, Gusella JF. Nat Commun. 2024 Apr 12;15(1):3182. doi: 10.1038/s41467-024-47485-0. PubMed
Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning. Silverstein RA, Kim N, Kroell AS, Walton RT, Delano J, Butcher RM, Pacesa M, Smith BK, Christie KA, Ha LL, Meis RJ, Clark AB, Spinner AD, Lazzarotto CR, Li Y, Matsubara A, Urbina EO, Dahl GA, Correia BE, Marks DS, Tsai SQ, Pinello L, De Ravin SS, Liu Q, Kleinstiver BP. Nature. 2025 Apr 22. doi: 10.1038/s41586-025-09021-y. PubMed

Associated Plasmids
Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs. Kinloch AJ, Rahman F, Karakas B, Shahid M, Lim B, Bouley SJ, Walker JA, Lee EF, Fairlie WD, Kelly KR, Cardone MH. Cancers (Basel). 2025 May 31;17(11):1852. doi: 10.3390/cancers17111852. PubMed
AI-guided Cas9 engineering provides an effective strategy to enhance base editing. Wei D, Cheng P, Song Z, Liu Y, Xu X, Huang X, Wang X, Zhang Y, Shu W, Wei Y. Mol Syst Biol. 2025 Nov;21(11):1563-1580. doi: 10.1038/s44320-025-00142-0. Epub 2025 Sep 15. PubMed
Noncanonical target-strand cytosine base editing via engineered Un1Cas12f1 platform. Song Z, Guo J, Fan Z, Huang S, Li G, Zhao Z, Chen B, Huang S, Zheng W, Wei Y, Chen Y, Huang X, Liu J, Wu L, Wang X. Nat Commun. 2025 Oct 28;16(1):9499. doi: 10.1038/s41467-025-64562-0. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.